Rabbit Anti-Human HTT (a.a. 803-941) Polyclonal antibody

Barley samples were treated hydrothermally (HTT) to modify their physical properties for the production of semolina. HTT has increased the hardness value and firming of the barley structure with more compactly packed starch in the protein matrix of grain with increase in treatment time. Treated barley samples were milled in laboratory roller mill which resulted in the production of four fractions namely husk (HK), coarse semolina (CS), fine semolina (FS) and flour (FL). Total semolina yield increased up to 20 min of steaming to 86.69% but decreased on further time increase. Barley pretreatment was found to be necessary to obtain increased yield and uniform sized firm semolina granules. Water holding capacity of semolina significantly increased (232 g/100 gm) with increase in the HTT time. The solubility index of semolina decreased (3.56%) with increase in the HIT time. Pasting temperature of semolina increased while viscosity decreased with increase an HTT time.

Introduction: Alkaptonuria is an iconic disease, dating back to the Egyptians and has continued to prove a valuable teaching tool to many medics as an example of an inborn error of metabolism. In recent years, much progress has been made on understanding the condition and its symptoms; the single defective gene has been identified and cloned. In humans, novel phenotypic presentations of the condition have been documented, and in vitro models developed to understand the disease. Furthermore, a mouse model has studied and most recently clinical trials into the effectiveness of nitisinone have been undertaken. Nitisinone has been on a miraculous journey from its discovery as a weed killer to its effective treatment in hereditary tyrosinemia type - 1. Areas covered: The authors describe research into nitisinone and its application in the model and human systems in both hereditary tyrosinemia type 1 (HTT-1) and Alkaptonuria. The published literature was searched for outputs relating to 'Alkaptonuria', 'ochronosis', 'nitisinone', 'hereditary tyrosinemia type 1'. Any paper not in English or had no translation were excluded. Expert opinion: Now nitisinone is being studied for use in Alkaptonuria and this paper documents the journey of AKU and the promising potential of nitisinone in the treatment of Alkaptonuria.